



(11) **EP 3 335 728 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**A61K 39/21 (2006.01)**

(48) Corrigendum issued on:  
**11.03.2020 Bulletin 2020/11**

(45) Date of publication and mention  
of the grant of the patent:  
**25.12.2019 Bulletin 2019/52**

(21) Application number: **18150843.3**

(22) Date of filing: **13.10.2009**

(54) **BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE**

BIOCHEMISCH STABILISierter HIV-1-ENV-TRIMER-IMPfSTOFF

VACCIN COMPRENANT UN TRIMÈRE DE ENV DE HIV-1 STABILISÉ BIOCHIMIQUEMENT

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL**  
**PT RO SE SI SK SM TR**

(30) Priority: **10.10.2008 US 104449 P**

(43) Date of publication of application:  
**20.06.2018 Bulletin 2018/25**

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
**09820044.7 / 2 340 038**

(73) Proprietors:  

- **Children's Medical Center Corporation**  
**Boston, MA 02115 (US)**
- **Beth Israel Deaconess Medical Center, Inc.**  
**Boston, MA 02215 (US)**

(72) Inventors:  

- **Harrison, Stephen C.**  
**Brighton, MA 02135 (US)**
- **Chen, Bing**  
**Chestnut Hill, MA 02467 (US)**
- **Barouch, Dan H.**  
**Boston, MA 02215 (US)**

- **Nikolola, Joseph P.**  
**Watertown, MA 02472 (US)**
- **Seaman, Michael Scott**  
**West Roxbury, MA 02132 (US)**

(74) Representative: **Leonard, Thomas Charles**  
**Kilburn & Strode LLP**  
**Lacon London**  
**84 Theobalds Road**  
**London WC1X 8NL (GB)**

(56) References cited:  

- **RODENBURG CYNTHIA M ET AL: "Near**  
**full-length clones and reference sequences for**  
**subtype C isolates of HIV type 1 from three**  
**different continents", AIDS RESEARCH AND**  
**HUMAN RETROVIRUSES, MARY ANN LIEBERT,**  
**US, vol. 17, no. 2, 20 January 2001 (2001-01-20),**  
**pages 161-168, XP002318557, ISSN: 0889-2229,**  
**DOI: 10.1089/08892220150217247**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 335 728 B8**

- BOWER JOSEPH F ET AL: "Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.", JOURNAL OF VIROLOGY MAY 2004, vol. 78, no. 9, May 2004 (2004-05), pages 4710-4719, XP002778528, ISSN: 0022-538X